Table 1.

Tissue testosterone (T) and dihydrotestosterone (DHT) levels in androgen-stimulated benign prostate (AS-BP) and recurrent prostate cancer (RCaP) specimens using LC/MS/MS and RIA

Recurrent prostate cancer patientAge (y)RaceSerum prostate–specific antigen* (ng/mL)Gleason sumBone metastasesAndrogen deprivation therapyInterval (mo) from androgen deprivation therapy to tissue acquisitionSurvival (mo) after tissue acquisitionTissue androgen assays (pmol/g tissue)
AS-BP PatientAge (y)RaceTissue androgen assays (pmol/g tissue)
LC/MS/MS
RIA
LC/MS/MS
RIA
TestosteroneDihydrotestosteroneTestosteroneDihydrotestosteroneTestosteroneDihydrotestosteroneTestosteroneDihydrotestosterone
169CA7.18T3cN0M0LHRH + flu30121.60.02.15.3159CA3.423.66.596.54
267AA534.68T2cNxMxorch92173.70.03.00.9250AA014.54.169.79
381AA9.38T3cNxM1borch + flu131513.64.910.22.3377CA1.216.84.516.73
475CA28.39T4NxM0LHRH43461.24.61.60.4466AA1.811.35.032.52
569CA79.010T4NxM1bLHRH + flu1961.70.02.10.3573AA2.5122.955.66
657AA5.89T3cNxM0orch1973.87.8<0.870.5667CA2.920.59.3723.34
765CA1.19T4NxM1bLHRH3773.87.8<0.870.5667CA2.920.59.3723.34
861AA199.09T4N2M1borch49198.66.72.10.5859CA1.213.22.435.11
978AA24.09T2cNxM01° hypogonadN/A119.82.82.10.7971CA2.99.85.217.09
1062AA32.39T3cN1M0flu111311.41.219.7813.21065CA1.414.3
1186AA28.09T1bNxM1borch481.10.02.6<0.261166AA1.611.2
1282CA53.010T3cNxM1borch77362.50.43.10.71264CA26.5
1360CA0.010T2bNxM1bLHRH → DES3647.21.3<0.87<0.261344CA2.710.7
1486CA10.310TxN1M0Lupron7270.00.01471CA2.813.7
1589CA36.59T2aNxM0orch7661.60.71562n/a2.813.7
1686AA5.610T2bNxM0orch8466.75.21667CA3.220.3
1769CA3.010T3cN1M0DES → orch27239.11.51769CA3.338.3
1869CA120.510T3cN2M1bflu → DES2731.10.01857CA3.912.4
Maximum89534.6924813.67.819.7813.2771338.39.3723.34
Upper quartile825372198.64.62.950.9693.217.15.217.09
Median69263711.53.751.252.080.4665.52.7513.74.516.54
Lower quartile655.82761.601.560.42591.611.32.955.66
Minimum570113000.870.264406.52.432.52
  • Abbreviations: CA, Caucasian; AA, African-American.